Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice

Anti-Cancer Drugs

Volumn 11, Issue 7, 2000, Pages 579-582

  Louvet, Christophe ^a   Coudray, Anne Marie ^a   Tournigand, Christophe ^a   Prévost, Sophie ^a   Raymond, Eric ^a   De Gramont, Aimery ^a   Chazard, Michel ^b   Gespach, Christian ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Folinic acid; Human colorectal cancer HT29 cell xenograft; Oxaliplatin; UFT

Indexed keywords

FOLINIC ACID; OXALIPLATIN; UFT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG FATALITY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HT29 CELLS; HUMANS; LEUCOVORIN; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; TEGAFUR; TRANSPLANTATION, HETEROLOGOUS; URACIL;

EID: 0033795561     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200008000-00010     Document Type: Article

References (17)

1. Phase II trial of UFF in advanced colorectal and gastric cancer
2. Phase II trial of UFT activity in pretreated breast cancer patients
3. Mechanism-based improvement in the therapeutic selectivity of 5FU prodrug alone and under conditions of metabolic modulation
4. 5-Fluorouracil prodrug: Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer
5. Randomized comparative study of Orzel (oral uracil/tegafur plus leucovorin) versus parenteral 5FU plus leucovorin in patients with metastatic colorectal cancer
6. Multicenter phase III study of 5FU or UTT in combination with leucovorin in patients with metastatic colorectal cancer
7. Oxaliplatin: Mechanism of action and antineoplastic activity
8. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells
9. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor A337 in human colon, breast and ovarian cancers
10. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
11. A randomized trial of leucovorin and 5FU with or without oxaliplatin in advanced colorectal cancer
12. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
13. Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer
14. Oxaliplatin for the treatment of advanced colorectal cancer: Future directions
15. Relationship of in vivo antitumor activities of fluorinated pyrimidines to thymidylate synthase activity and intratumoral concentrations of 5-Fluorouracil and uracil
16. Effects of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
17. Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice